Please assess the completion status of the following clinical trial:

Trial Title: Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Parents have been informed properly regarding the study and signed the informed consent form~* Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial~Exclusion Criteria:~* Subjects concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate, or severe illness, especially infectious diseases or fever (axillary temperature \>=37oC)~* Known history of allergy to egg and/or chicken protein or any other component of the vaccines~* Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Subject who has received a treatment likely to alter the immune response in the previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\>2 weeks)).~* Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives.~* Subjects has been immunized with influenza vaccine within 1 year~* Subjects receives any vaccination within 1 months before and after immunization of Flubio.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).